|
"shan ys"的相關文件
顯示項目 1-50 / 133 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-09-01 |
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study
|
Tsai, HJ;Chen, MH;Wang, HP;Hsiao, CF;Chen, YY;Chen, JS;Yang, MD;Tzen, CY;Shan, YS;Bai, LY;Chan, DC;Chu, PY;Ho, CL;Yang, Y;Lin, J;Lin, HY;Chang, CS;Wang, CC;Hwang, TL;Chen, LT |
| 國家衛生研究院 |
2025-07-07 |
Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition
|
Kuo, TL;Hou, YC;Shan, YS;Chen, LT;Hung, WC |
| 國家衛生研究院 |
2025-07 |
5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
|
Trovato, G;Rossini, D;Su, YY;Shan, YS;Chou, WC;Bagala, C;Bensi, M;Niger, M;Marchesi, S;Garattini, SK;Michelotti, A;Chiang, NJ;Pretta, A;Scartozzi, M;Vivaldi, C;Bartalini, L;Procaccio, L;Chen, LT;Tortora, G;Salvatore, L |
| 國家衛生研究院 |
2025-05-29 |
Macrophage activation determines muscle wasting in pancreatic cancer
|
Chang, CJ;Huang, PH;Chen, SY;Su, PC;Ding, LY;Hou, YC;Hung, MN;Chen, KL;Wu, YN;Wu, SR;Lin, FC;Lu, PJ;Wu, HY;Chen, YJ;Chang, CH;Chang, CP;Hwang, DY;Wang, YC;Shan, YS |
| 國家衛生研究院 |
2025-04-22 |
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
|
Chiang, NJ;Lee, JH;Chen, MH;Chao, Y;Su, WC;Bai, LY;Wu, SY;Hsu, CH;Shan, YS;Li, CP;Chen, SH;Chung, WP;Hao, WH;Chen, LT;Lin, CC |
| 國家衛生研究院 |
2025-03 |
Single-cell RNA sequencing via endoscopic ultrasound-guided fine-needle biopsy for pancreatic tumors uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Hsu, CW;Yeh, CM;Yu, CC;Hou, YC;Huang, CJ;Liu, YS;Chao, YJ;Wang, DY;Shan, YS;Chen, LC |
| 國家衛生研究院 |
2025-01-18 |
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells
|
Wang, CA;Hou, YC;Hong, YK;Tai, YJ;Shen, CH;Hou, PC;Fu, JL;Wu, CL;Cheng, SM;Hwang, DY;Su, YY;Shan, YS;Tsai, SJ |
| 國家衛生研究院 |
2024-09 |
TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
|
Su, YY;Bai, LY;Huang, CJ;Chiu, CF;Wang, HT;Du, JS;Wang, HC;Chuang, S;Shih, YH;Lin, HC;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2024-07-11 |
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study
|
Tsai, HJ;Shan, YS;Yang, CY;Hsiao, CF;Tsai, CH;Wang, CC;Lin, MT;Ting, CF;Chan, DC;Chen, TH;Yen, CC;Chen, YY;Lin, HY;Yeh, TS;Ho, CL;Shieh, TY;Bai, LY;Hsu, JT;Chen, IS;Chen, LT;Yeh, CN;Liu, TW;Chuang, CH;Wang, TE |
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2024-03-25 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang, CY;Yang, SH;Li, CP;Su, YY;Chiu, SC;Bai, LY;Shan, YS;Chen, LT;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chiang, NJ;Chou, WC |
| 國家衛生研究院 |
2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan
|
Cheng, SM;Su, YY;Chiang, NJ;Wang, CJ;Chao, YJ;Huang, CJ;Tsai, HJ;Chen, SH;Chang, CY;Tsai, CR;Li, YJ;Yen, CJ;Chuang, SC;Chang, JSM;Shan, YS;Hwang, DY;Chen, LT |
| 國家衛生研究院 |
2023-Auh-15 |
Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination
|
Hung, YH;Hou, YC;Hsu, SH;Wang, LY;Tsai, YL;Shan, YS;Su, YY;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Yeh, CM;Yu, CC;Hsu, CW;Shan, YS;Huang, DY;Chen, LT |
| 國家衛生研究院 |
2023-07-04 |
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen, CC;Yang, YH;Ku, HY;Hu, HM;Lo, SS;Chang, HC;Chao, Y;Chen, JS;Wang, HP;Wang, TE;Bai, LY;Wu, MS;Yen, CJ;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2023-06-08 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study
|
Su, YY;Chao, YJ;Wang, CJ;Liao, TK;Su, PJ;Huang, CJ;Chiang, NJ;Yu, YT;Tsai, HM;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors
|
Lin, CC;Chiang, NJ;Lee, JH;Chen, MH;Chao, Y;Su, WC;Bai, LY;Wu, SY;Hsu, CH;Shan, YS;Li, CP;Chen, SH;Chung, WP;Chen, LT |
| 國家衛生研究院 |
2023-04-11 |
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized
|
Chiu, YF;Liu, TW;Shan, YS;Chen, JS;Li, CP;Ho, CL;Hsieh, RK;Hwang, TL;Chen, LT;Ch'ang, HJ; Taiwan Cooperative Oncology Group pancreatic cancer study group, |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-02 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
|
Su, YY;Chiang, NJ;Chang, JS;Wang, YW;Shen, BN;Li, YJ;Hwang, DY;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-12-15 |
An integrated microfluidic system for cholangiocarcinoma diagnosis from bile by using specific affinity probes
|
Lu, TH;Chiang, NJ;Tsai, YC;Gopinathan, P;Huang, CJ;Chang, JL;Tu, HC;Shan, YS;Hung, SC;Lee, GB |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-11-06 |
PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation
|
Chang, TM;Chu, PY;Lin, HY;Huang, KW;Hung, WC;Shan, YS;Chen, LT;Tsai, HJ |
| 國家衛生研究院 |
2022-10 |
An integrated microfluidic device for automated detection of cancer cells from bile for cholangiocarcinoma prognosis
|
Chang, JL;Tsai, YC;Chiang, NJ;Huang, CJ;Huang, YS;Hung, SC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chen, YY;Hsueh, SW;Yang, SH;Chiu, SC;Chiang, NJ;Chiu, TJ;Li, CP;Bai, LY;Chiu, CF;Chuang, SC;Shan, YS;Chan, DCA;Chen, LT;Yen, CJ;Peng, CM;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2022-08-19 |
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer
|
Park, JM;Peng, JM;Shen, YS;Lin, CY;Hsu, TW;Su, YH;Chen, HA;Saengboonmee, C;Chang, JS;Chiu, CF;Shan, YS |
| 國家衛生研究院 |
2022-07-18 |
Impaired chromatin remodeling predicts survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: A phase II T1219 study
|
Chiang, NJ;Tan, KT;Bai, LY;Hsiao, CF;Huang, CY;Hung, YP;Huang, CJ;Chen, SC;Shan, YS;Chao, Y;Huang, YH;Lee, IC;Lee, PC;Su, YY;Chen, SJ;Yeh, CN;Chen, LT;Chen, MH |
| 國家衛生研究院 |
2022-07-03 |
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma
|
Chiang, NJ;Hou, YC;Tan, KT;Tsai, HW;Lin, YJ;Yeh, YC;Chen, LT;Hou, YF;Chen, MH;Shan, YS |
| 國家衛生研究院 |
2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
|
Ting, YL;Su, YY;Chiang, NJ;Chao, YJ;Li, YJ;Huang, CJ;Liao, TK;Su, PJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer
|
Chen, MH;Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, LT |
| 國家衛生研究院 |
2022-06-26 |
The differential clinical impacts of cachexia and sarcopenia on the prognosis of advanced pancreatic cancer
|
Hou, YC;Chen, CY;Huang, CJ;Wang, CJ;Chao, YJ;Chiang, NJ;Wang, HC;Tung, HL;Liu, HC;Shan, YS |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-06-16 |
Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: A prospective cohort study
|
Huang, CJ;Huang, WY;Chen, CY;Chao, YJ;Chiang, NJ;Shan, YS |
| 國家衛生研究院 |
2022-06 |
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma
|
Chiang, NJ;Tan, KT;Huang, CY;Chen, MH;Chiu, TJ;Shan, YS;Li, CF;Chen, LT |
| 國家衛生研究院 |
2022-05-15 |
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience
|
Su, YY;Ting, YL;Wang, CJ;Chao, YJ;Liao, TK;Su, PJ;Chiang, NJ;Liao, IC;Yu, YT;Liu, YS;Tsai, HM;Li, YJ;Huang, CJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-24 |
Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway
|
Hung, YH;Hsu, SH;Hou, YC;Chu, PY;Su, YY;Shan, YS;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2021-12-17 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su, YY;Chiu, YF;Li, CP;Yang, SH;Lin, J;Lin, SJ;Chang, PY;Chiang, NJ;Shan, YS;Ch’ang, HJ;Chen, LT |
| 國家衛生研究院 |
2021-11-30 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu, HM;Tsai, HJ;Ku, HY;Lo, SS;Shan, YS;Chang, HC;Chao, Y;Chen, JS;Chen, SC;Chiang, CJ;Li, AF;Wang, HP;Wang, TE;Bai, LY;Wu, MS;Chen, LT;Liu, TW;Yang, YH |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience
|
Tsai, HJ;Hsiao, CF;Chang, JS;Chen, LT;Chao, YJ;Yen, CJ;Shan, YS |
| 國家衛生研究院 |
2021-11-01 |
Exfoliated tumor cells in bile as a promising indicator of disease status in cholangiocarcinoma
|
Gopinathan, P;Lu, TH;Chiang, NJ;Huang, CJ;Tu, HC;Hung, SC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, L;Chen, MH |
| 國家衛生研究院 |
2021-07-15 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, YS;Chen, LT;Wu, CH;Chang, YF;Lee, CT;Chiang, NJ;Chao, YJ;Yen, CJ;Tsai, HJ;Huang, HE;Tsai, CR;Weng, YL;Yang, HC;Liu, HC;Chang, JS |
| 國家衛生研究院 |
2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial
|
Pen, SL;Shan, YS;Hsiao, CF;Liu, TW;Chen, JS;Ho, CL;Chou, WC;Hsieh, RK;Chen, LT;Ch'ang, HJ |
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 國家衛生研究院 |
2021-04-12 |
An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Chu, PY;Tsai, CR;Tsai, HJ |
顯示項目 1-50 / 133 (共3頁)
1 2 3 > >>
每頁顯示[10|25|50]項目
|
